All In MedTech

Device Trial Radar · NCT00270946

Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers

A Pivotal Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers

Last checked: Nov 20, 2026Latest source record: Dec 29, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Apr 2002

Primary completion

Not stated

Study completion Dec 2003

Sponsor

Lead sponsor
Ortec InternationalNot on our public-company list
Sponsor type
Industry
First posted
Dec 29, 2005

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the clinical benefits and safety of OrCel in the treatment of venous ulcers. OrCel and standard care were compared to standard care alone. Standard care consisted of currently accepted compression therapy. Patients were treated for 12 weeks. Patients with healed ulcers were followed for an additional 12 weeks to assess durability of the healed wound.

Conditions

  • Venous Leg Ulcer
  • Venous Stasis Ulcer

Interventions

  • Bilayered Cellular Matrix (OrCel)Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator assessment of wound healing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Terry Treadwell, MD

    Montgomery, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.